GO:0097141 BIM-BCL-2 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097141 describes the BIM-BCL-2 heterodimeric protein complex, a direct physical interaction between the pro-apoptotic BH3-only protein BIM and the anti-apoptotic guardian BCL-2.
• The BIM-BCL-2 complex is a key node in the intrinsic (mitochondrial) apoptosis pathway: BIM binding neutralizes BCL-2, freeing BAX/BAK to permeabilize mitochondria.
• Failure to form or sustain BIM-BCL-2 complexes is linked to glucocorticoid resistance in chronic lymphocytic leukemia and to venetoclax resistance in t(14;18) lymphoma.
• BH3 mimetics such as venetoclax (ABT-199) and BH3-M6 disrupt anti-apoptotic protein-protein interactions, including BIM-BCL-2, to trigger apoptosis in cancer cells.
• BIM and BMF are BH3-only sensors whose deregulation contributes to malignant disease and tissue homeostasis defects.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect whether BIM-BCL-2 complex formation is causal in drug response and tumor survival.
Description
The BIM-BCL-2 complex (GO:0097141) is a cellular_component term describing a heterodimeric protein complex formed by BIM (BCL-2 interacting mediator of cell death) and BCL-2, two members of the Bcl-2 family of anti- and pro-apoptotic regulators. This complex sits at the decision point of the intrinsic apoptosis pathway, where pro-apoptotic BH3-only proteins engage anti-apoptotic guardians to control mitochondrial outer membrane permeabilization. Because the balance between BIM and BCL-2 determines whether a cell survives or dies, the BIM-BCL-2 complex is a central research focus in oncology, hematology, and drug-resistance studies. Experimental evidence shows that BH3 alpha-helical mimics can disrupt Bcl-2 family protein-protein interactions, including those involving Bim, and induce apoptosis in a Bax- and Bim-dependent manner. In parallel, glucocorticoid resistance in chronic lymphocytic leukemia has been associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. These findings make GO:0097141 a high-value target for mechanistic studies and therapeutic development.
BIM-BCL-2 complex At A Glance
| GO ID | GO:0097141 |
|---|---|
| GO term | BIM-BCL-2 complex |
| Ontology | cellular_component |
| Synonym | None |
| Definition | A heterodimeric protein complex consisting of BIM and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators. |
| Major function | Mediates pro-apoptotic BIM sequestration of anti-apoptotic BCL-2, regulating mitochondrial apoptosis. |
| Complex type | Heterodimer of one BIM molecule and one BCL-2 molecule. |
| Pathway context | Intrinsic (mitochondrial) apoptosis; Bcl-2 family protein-protein interaction network. |
| Disease relevance | Venetoclax resistance in lymphoma, glucocorticoid resistance in CLL, multiple myeloma, neuroblastoma. |
What Is GO:0097141?
GO:0097141 defines a heterodimeric protein complex consisting of BIM and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators. In practical terms, it is the physical assembly through which the pro-apoptotic BH3-only protein BIM binds and sequesters the anti-apoptotic protein BCL-2, thereby modulating apoptotic signaling at the mitochondrion.
Why Is BIM-BCL-2 complex Important in Cell Biology?
The BIM-BCL-2 complex is important because it represents a direct molecular handshake between a death-promoting BH3-only protein and a survival-promoting Bcl-2 family member, and the outcome of this interaction determines whether cells undergo apoptosis. In cancer, overexpression of BCL-2 or loss of BIM function can shift the balance toward survival, contributing to resistance to chemotherapy and targeted agents such as venetoclax. Understanding how BIM-BCL-2 complexes assemble, stabilize, and dissociate is therefore essential for predicting drug responses and designing combination therapies.
BIM-BCL-2 complex
• Controls the intrinsic apoptosis checkpoint by neutralizing BCL-2.
• Directly implicated in glucocorticoid resistance in chronic lymphocytic leukemia.
• Linked to acquired venetoclax resistance in t(14;18) positive lymphoma.
• Targeted by BH3 mimetics such as BH3-M6 and venetoclax.
• Relevant to multiple myeloma where HDAC inhibition is combined with BCL-2 inhibition.
• Relevant to neuroblastoma with high BCL-2 expression.
• BIM and BMF deregulation contributes to malignant disease and tissue homeostasis defects.
• Provides a mechanistic readout for CRISPR-based functional genomics of apoptosis.
What Happens During BIM-BCL-2 complex?
(未命名小节)
In simple terms: BIM grabs BCL-2 so that BCL-2 cannot block cell death.
During apoptosis signaling, the BH3-only protein BIM binds to the anti-apoptotic protein BCL-2 to form the BIM-BCL-2 heterodimer. This interaction sequesters BCL-2 and prevents it from inhibiting the effector proteins BAX and BAK. In glucocorticoid-resistant chronic lymphocytic leukemia, upregulated Bim/Bcl-2 complexes fail to activate Bax and Bak, illustrating that complex formation alone is not always sufficient for apoptosis execution. BH3 mimetics can disrupt Bcl-2 family interactions with Bax, Bak, Bad, or Bim and induce apoptosis in a Bax- and Bim-dependent manner.
Structure and Composition of BIM-BCL-2 complex
In simple terms: The complex is a two-protein pair: one BIM molecule and one BCL-2 molecule.
GO:0097141 defines a heterodimeric protein complex consisting of BIM and BCL-2. BIM is a BH3-only pro-apoptotic protein, while BCL-2 is an anti-apoptotic multi-domain member of the Bcl-2 family. The interaction is mediated by the BH3 alpha-helix of BIM docking into the hydrophobic groove of BCL-2. Structural and modeling studies of BIM SAHB (stabilized alpha helix of BCL2) indicate that BIM-derived helices can engage BCL-2 family proteins, though not always productively activating BAX.
Molecular Mechanism of BIM-BCL-2 complex
In simple terms: BIM inserts its BH3 helix into BCL-2, blocking BCL-2's survival function.
The molecular mechanism centers on BH3-in-groove binding: the BH3 domain of BIM occupies the hydrophobic binding pocket of BCL-2, forming a stable heterodimer. This binding neutralizes BCL-2 and lowers the threshold for BAX/BAK activation. BH3 mimetics such as BH3-M6 disrupt Bcl-XL, Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim, mimicking the action of BIM. Venetoclax (ABT-199) similarly targets BCL-2 and can be combined with MCL-1 inhibition to overcome resistance.
Regulation of BIM-BCL-2 complex
In simple terms: Cells adjust BIM and BCL-2 levels to decide whether to live or die.
The abundance and activity of BIM and BCL-2 are regulated transcriptionally and post-translationally, and the ratio of BIM to BCL-2 determines the extent of complex formation. In glucocorticoid-resistant CLL, upregulated Bim/Bcl-2 complexes are present but fail to activate Bax and Bak, suggesting that additional regulatory layers control apoptosis execution. Acquired resistance to venetoclax in t(14;18) positive lymphoma further demonstrates that cancer cells can adapt Bcl-2 family interactions to evade apoptosis. HDAC inhibition combined with MEK or BCL-2 inhibition modulates apoptosis in multiple myeloma, indicating that epigenetic and signaling pathways converge on Bcl-2 family complexes.
Key Genes Involved in GO:0097141 BIM-BCL-2 complex
The following genes and proteins are directly or functionally linked to the BIM-BCL-2 complex (GO:0097141) based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCL2 | Anti-apoptotic protein; binds BIM to form the BIM-BCL-2 complex | Target of venetoclax; overexpression drives lymphoma and neuroblastoma survival |
| BCL2L11 (BIM) | Pro-apoptotic BH3-only protein; binds and neutralizes BCL-2 | Central to glucocorticoid resistance and BH3 mimetic response |
| BAX | Effector pro-apoptotic protein activated downstream of BIM-BCL-2 | Required for apoptosis after BH3 mimetic treatment |
| BAK | Effector pro-apoptotic protein; activated by BIM-BCL-2 imbalance | Required for apoptosis after BH3 mimetic treatment |
| BAD | BH3-only protein; interacts with Bcl-2 family proteins | Disrupted by BH3-M6; modulates apoptosis |
| MCL1 | Anti-apoptotic Bcl-2 family member | Combination target with BCL-2 inhibition in neuroblastoma |
| BCL2L1 (BCL-XL) | Anti-apoptotic Bcl-2 family member | Disrupted by BH3-M6; interacts with Bim |
| BMF | BH3-only protein related to BIM | Deregulated in malignant disease and tissue homeostasis |
| TP53 | Tumor suppressor upstream of apoptosis | Context for apoptosis competence in cancer models |
| NRAS | Oncogenic driver in neuroblastoma | RAS-mutant neuroblastoma models for targeted therapy |
| KRAS | Oncogenic driver in RAS-mutant cancers | RAS-mutant neuroblastoma models for targeted therapy |
| HDAC1/2 | Histone deacetylases modulating apoptosis | HDAC inhibition combined with BCL-2 inhibition in myeloma |
| MEK1/2 | Kinases in RAS-MAPK pathway | MEK inhibition combined with HDAC or BCL-2 inhibition |
| CASP3 | Executioner caspase | Downstream of mitochondrial apoptosis |
| CASP9 | Initiator caspase in intrinsic apoptosis | Downstream of BIM-BCL-2 complex |
| APAF1 | Apoptosome component | Downstream of mitochondrial apoptosis |
| CYCS | Cytochrome c released upon MOMP | Downstream of BIM-BCL-2 complex |
| BID | BH3-only protein crosstalk | Modulates Bcl-2 family interactions |
How Is BIM-BCL-2 complex Regulated?
The BIM-BCL-2 complex is regulated by the balance of BIM and BCL-2 expression, post-translational modifications, and upstream signaling pathways such as RAS-MAPK and HDAC-dependent epigenetic programs. In glucocorticoid-resistant CLL, upregulated Bim/Bcl-2 complexes fail to activate Bax and Bak, indicating that complex formation is necessary but not sufficient for apoptosis. Acquired venetoclax resistance in t(14;18) positive lymphoma further shows that cancer cells can rewire Bcl-2 family interactions to survive. HDAC inhibition combined with MEK or BCL-2 inhibition modulates apoptosis in multiple myeloma, highlighting crosstalk between epigenetic regulation and Bcl-2 family complexes.
BIM-BCL-2 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCL2 | Lymphoma, neuroblastoma, multiple myeloma | BCL2 overexpression and venetoclax-resistant cell lines |
| BCL2L11 (BIM) | Glucocorticoid-resistant CLL | BIM knockout and point-mutation models |
| BAX/BAK | Apoptosis execution defects | BAX/BAK double knockout cells |
| MCL1 | Neuroblastoma survival | MCL1 overexpression and combination therapy models |
| HDAC1/2 | Multiple myeloma | HDAC inhibitor-treated myeloma cells |
BIM-BCL-2 complex in lymphoma and venetoclax resistance
Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells is associated with altered Bcl-2 family interactions, including those involving BIM and BCL-2. Because venetoclax directly targets BCL-2, changes in BIM-BCL-2 complex dynamics can determine whether lymphoma cells survive or die under therapy.
BIM-BCL-2 complex in chronic lymphocytic leukemia and glucocorticoid resistance
Glucocorticoid resistance in chronic lymphocytic leukemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. This finding links GO:0097141 directly to a clinically important drug-resistance phenotype and suggests that BIM-BCL-2 complex function, not just abundance, matters for therapy response.
BIM-BCL-2 complex in multiple myeloma and neuroblastoma
In multiple myeloma, HDAC inhibition combined with MEK or BCL-2 inhibition modulates apoptosis, implicating Bcl-2 family complexes in combination therapy strategies. In neuroblastoma, high BCL-2 expression predicts efficacy of ABT-199 (venetoclax), and combination with MCL-1 inhibition is rational. RAS-mutant neuroblastoma models further highlight the need for targeted therapies that intersect with apoptosis signaling.
From BIM-BCL-2 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does BIM-BCL-2 complex formation drive apoptosis? | BIM knockout and BCL2 overexpression cell lines |
| Which BH3 domain residues mediate BCL-2 binding? | Point-mutation knock-in of BIM BH3 domain |
| Can BH3 mimetics disrupt BIM-BCL-2 complexes? | Tagged knock-in BIM and BCL-2 for FRET/BRET |
| Does BCL-2 overexpression confer venetoclax resistance? | BCL2 overexpression in lymphoma cell lines |
| Is MCL-1 a compensatory survival factor? | MCL1 knockout or overexpression with BCL-2 inhibition |
| Do epigenetic modifiers regulate BIM-BCL-2 complexes? | HDAC inhibitor-treated myeloma models |
How to Study the BIM-BCL-2 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical BIM-BCL-2 interaction | Detect complex in cell lysates |
| Proximity ligation assay | In situ complex formation | Quantify BIM-BCL-2 in fixed cells |
| FRET/BRET | Real-time protein-protein interaction | Live-cell complex dynamics |
| Annexin V / caspase assay | Apoptosis execution | BH3 mimetic response |
| CRISPR knockout screen | Genetic dependency | Identify modulators of apoptosis |
| RNA-seq | Transcriptional changes | Resistance mechanisms |
| Proteomics | Protein abundance and interactions | Bcl-2 family network mapping |
| Structural modeling | BH3-in-groove binding | Predict BIM-BCL-2 interface |
Co-immunoprecipitation and proximity assays
Co-immunoprecipitation of BIM with BCL-2 remains a standard method to detect the BIM-BCL-2 complex in cell lysates. Proximity ligation assays and FRET/BRET with tagged knock-in proteins can quantify complex formation in live cells.
Apoptosis phenotyping
Annexin V staining, caspase-3/7 activity, and mitochondrial outer membrane permeabilization assays measure the functional consequence of BIM-BCL-2 complex disruption. These readouts are essential when testing BH3 mimetics such as venetoclax or BH3-M6.
CRISPR functional genomics
CRISPR knockout screens targeting BCL2, BCL2L11, BAX, BAK, and MCL1 can identify genetic dependencies that modulate BIM-BCL-2 complex function. Point-mutation knock-in of BH3 domain residues allows precise structure-function mapping.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can quantify BIM and BCL-2 expression and identify co-regulated apoptosis genes in resistant versus sensitive models. These datasets help prioritize candidate genes for CRISPR validation.
How CRISPR Can Be Used to Study GO:0097141 BIM-BCL-2 complex
Knockout
CRISPR knockout of BCL2L11 (BIM) or BCL2 can abolish BIM-BCL-2 complex formation and reveal its role in apoptosis and drug response. Knockout of BAX or BAK is used to test whether apoptosis downstream of the complex requires these effectors.
Point Mutation
Point-mutation knock-in of BH3 domain residues in BIM can disrupt BCL-2 binding while preserving other interactions, enabling precise structure-function studies of GO:0097141.
Knock-in
Tagged knock-in of BIM or BCL-2 with fluorescent or affinity tags allows real-time imaging and biochemical isolation of the BIM-BCL-2 complex. This approach is valuable for testing BH3 mimetics in live cells.
Overexpression
Overexpression of BCL2 confers resistance to apoptosis and is used to model venetoclax resistance in lymphoma and neuroblastoma. Overexpression of BIM can shift the balance toward apoptosis and sensitize cells to BH3 mimetics.
How EDITGENE Supports BIM-BCL-2 complex Research
Researchers studying BIM-BCL-2 complex-related genes often need to determine whether a candidate gene is causally involved in apoptosis, drug resistance, or tumor survival. EDITGENE provides publication-ready CRISPR models and screening services to test these hypotheses with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for BIM-BCL-2 complex research.
Frequently Asked Questions About BIM-BCL-2 complex
What is the BIM-BCL-2 complex?
The BIM-BCL-2 complex (GO:0097141) is a heterodimeric protein complex consisting of BIM and BCL-2, members of the Bcl-2 family of anti- and proapoptotic regulators.
What genes are involved in the BIM-BCL-2 complex?
The core genes are BCL2 and BCL2L11 (BIM), with functional partners including BAX, BAK, BAD, MCL1, and BMF.
What is the function of GO:0097141?
GO:0097141 mediates pro-apoptotic BIM sequestration of anti-apoptotic BCL-2, regulating mitochondrial apoptosis.
How is the BIM-BCL-2 complex linked to cancer?
Altered BIM-BCL-2 complex function is linked to venetoclax resistance in lymphoma, glucocorticoid resistance in CLL, and survival in multiple myeloma and neuroblastoma.
What drugs target the BIM-BCL-2 complex?
BH3 mimetics such as venetoclax (ABT-199) and BH3-M6 disrupt Bcl-2 family protein-protein interactions, including BIM-BCL-2.
How can I study the BIM-BCL-2 complex in the lab?
Co-immunoprecipitation, proximity ligation, FRET/BRET, apoptosis assays, and CRISPR knockout or knock-in models are commonly used.
Why do some Bim/Bcl-2 complexes fail to activate Bax and Bak?
In glucocorticoid-resistant CLL, upregulated Bim/Bcl-2 complexes fail to activate Bax and Bak, indicating that complex formation alone is not sufficient for apoptosis.
What is the role of BIM in apoptosis?
BIM is a BH3-only pro-apoptotic protein that binds and neutralizes anti-apoptotic BCL-2, lowering the threshold for BAX/BAK activation.
Can CRISPR knockout help study BIM-BCL-2 complex function?
Yes, CRISPR knockout of BCL2, BCL2L11, BAX, or BAK can reveal genetic dependencies and apoptosis mechanisms.
What cell models are used for venetoclax resistance research?
t(14;18) positive lymphoma cells with acquired venetoclax resistance and BCL-2 high-expressing neuroblastoma models are commonly used.
Conclusion
The BIM-BCL-2 complex (GO:0097141) is a central heterodimeric node in the intrinsic apoptosis pathway, where pro-apoptotic BIM engages anti-apoptotic BCL-2 to control cell fate. Its dysfunction is linked to glucocorticoid resistance in CLL, venetoclax resistance in lymphoma, and survival advantages in multiple myeloma and neuroblastoma. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with BH3 mimetic testing and functional genomics, provide a rigorous path to dissect this complex and identify therapeutic opportunities.
References
- 1. Hill RD et al.. 2026. Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.. bioRxiv PMID: 41756844
- 2. Bodo J et al.. 2016. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.. Oncotarget 7(43):70000-70010 PMID: 27661108
- 3. Verma S et al.. 2016. BIM (BCL-2 interacting mediator of cell death) SAHB (stabilized α helix of BCL2) not always convinces BAX (BCL-2-associated X protein) for apoptosis.. J Mol Graph Model 67:94-101 PMID: 27262527
- 4. Kazi A et al.. 2011. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.. J Biol Chem 286(11):9382-92 PMID: 21148306
- 5. Bate-Eya LT et al.. 2016. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.. Oncotarget 7(19):27946-58 PMID: 27056887
- 6. Ramakrishnan VG et al.. 2019. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.. Haematologica 104(10):2061-2074 PMID: 30846494
- 7. Melarangi T et al.. 2012. Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.. Cell Death Dis 3(8):e372 PMID: 22898870
- 8. Piñon JD et al.. 2008. Bim and Bmf in tissue homeostasis and malignant disease.. Oncogene 27 Suppl 1(Suppl 1):S41-52 PMID: 19641506
